Pharma 'Muckraker' Top Choice for New Journalism Project
Reporter Glenn Greenwald, who has been in the news recently for disseminating the whistle-blower and former CIA employee Edward Snowden’s information on the US’s mass surveillance program has left The Guardian where his initial articles appeared
Reporter Glenn Greenwald, who has been in the news recently for disseminating the whistle-blower and former CIA employee Edward Snowden’s information on the US’s mass surveillance program has left The Guardian where his initial articles appeared. Along with filmmaker Laura Poitras (also covering the Snowden story) and Jeremy Scahill, Greenwald is joining up with Pierre Omidyar, one of the founders of Ebay, who has announced that he’s funding a journalism project with $250 million dollars in seed money.
It’s intriguing media news in a world where the line between editorial and advertising is increasingly blurred, and publications are dying off like flies.
Omidyar intends to publish progressive, long-form, investigative stories written by the country’s best specialist writers on a variey of different subjects.
Whose on his dream team? He published his wish list on Tuesday on Opednews.com.
And who would he pick to cover the pharma industry? Martha Rosenberg, he says, “who does great investigative reporting on food and drug safety and Big Pharma and Big Agra.”
Her work is certainly provocative and hardhitting, and sometimes loads of fun to read, but is it fair?
Writing for a variey of publications, here are just a few of her recent titles:
6 New Ways Big Pharma Is Scheming to Make Billions at the Expense of Your Health
Big Pharma Company Mocked Patients Who Got “Jawbone Death” from Drug
How Kids Are Getting Hooked on Pills for Life
You get the idea. My personal point of view is that it’s easy to muckrake, but a lot harder to dig deep to reveal texture and complexity of a topic. But we will wait and see. There’s always room for other voices.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.
